Skip to main content
SpringerLink
Log in

Nebivolol

In the Treatment of Hypertension in the US

  • Adis Drug Profile
  • Published:
American Journal of Cardiovascular Drugs Aims and scope Submit manuscript

Abstract

▲ Nebivolol is a β-adrenergic receptor antagonist with a dual mechanism of action. It shows high selectivity for β1-adrenergic receptors and appears to have nitric oxide-mediated vasodilatory activity.

▲ Once-daily nebivolol effectively lowered BP in patients with mild to moderate hypertension in four randomized, double-blind, placebo-controlled, 12-week trials. Trough sitting DBP and SBP were reduced to a significantly greater extent in nebivolol than in placebo recipients in trials in demographically heterogenous hypertensive patient groups, as well as in trials involving only Black patients and in patients continuing previous stable antihypertensive drug therapies.

▲ Treatment response (defined as a mean sitting DBP <90 mmHg or a ≥10 mmHg reduction from baseline) rates were significantly higher in nebivolol versus placebo recipients in trials enrolling patient groups considered representative of the US hypertensive population (46–65% vs 25%), in Black patients (57–64% vs 27%), and in patients concurrently treated with other antihypertensive drugs (53–65% vs 41%).

▲ Nebivolol was generally well tolerated in the treatment of hypertension, with the majority of adverse events described as being mild or moderate in severity. The incidences of fatigue, bradycardia, dyspnea, depression, and erectile dysfunction (events commonly associated with β-adrenergic receptor antagonist use) did not significantly differ between nebivolol and placebo recipients in the 12-week trials.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Roberts WC, Black HR, Bakris GL, et al. The editor’s roundtable: revisiting the role of β-blockers in hypertension. Am J Cardiol 2007 Jul 15; 100(2): 253–67.

    Article  PubMed  Google Scholar 

  2. Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003 Dec; 42(6): 1206–52.

    Article  PubMed  CAS  Google Scholar 

  3. AACE Diabetes Mellitus Clinical Practice Guidelines Task Force. American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus: hypertension management. Endocr Pract 2007; 13 Suppl. 1: 35–40

    Google Scholar 

  4. A.Menarini Pharma U.K. S.R.L. Nebilet 5mg tablets: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/medicine/9145/SPC/Nebilet%205mg%20Tablets/ [Accessed 2009 Mar 11].

  5. Forest Laboratories Inc. Bystolic® (nebivolol) tablets 2.5mg, 5mg, 10mg and 20mg: US prescribing information [online]. Available from URL: http://www.frx.com/pi/bystolic_pi.pdf [Accessed 2009 Mar 5].

  6. Forest Laboratories Inc. Forest Laboratories, Inc. announces amendment to Bystolic® (nebivolol) agreement [media release: 2008 Feb 27; online]. Available from URL: http://www.frx.com/news/PressRelease.aspx?ID=1113275 [Accessed 2009 Jul 3].

  7. McNeely W, Goa KL. Nebivolol in the management of essential hypertension: a review. Drugs 1999 Apr; 57(4): 633–51.

    Article  PubMed  CAS  Google Scholar 

  8. Moen MD, Wagstaff AJ. Nebivolol: a review of its use in the management of hypertension and chronic heart failure. Drugs 2006; 66(10): 1389–409.

    Article  PubMed  CAS  Google Scholar 

  9. Himmelmann A, Hedner T, Snoeck E, et al. Haemodynamic effects and pharmacokinetics of oral d- and l-nebivolol in hypertensive patients. Eur J Clin Pharmacol 1996; 51(3–4): 259–64.

    Article  PubMed  CAS  Google Scholar 

  10. Zanchetti A. Clinical pharmacodynamics of nebivolol: new evidence of nitric oxide-mediated vasodilating activity and peculiar haemodynamic properties in hypertensive patients. Blood Press Suppl 2004 Oct; 13 Suppl. 1: 17–32.

    Article  Google Scholar 

  11. Van de Water A, Janssens W, Van Neuten J, et al. Pharmacological and hemodynamic profile of nebivolol, a chemically novel, potent, and selective β1-adrenergic antagonist. J Cardiovasc Pharmacol 1988; 11(5): 552–63.

    Article  PubMed  Google Scholar 

  12. Bristow MR, Nelson P, Winobe W, et al. Characterization of β1-adrenergic receptor selectivity of nebivolol and various other β-blockers in human myocardium [abstract no. P-121]. Am J Hypertens 2005; 18(5 Pt 2): 51–2.

    Article  Google Scholar 

  13. Mason RP. Nitric oxide mechanisms in the pathogenesis of global risk. J Clin Hypertens (Greenwich) 2006 Aug; 8(8 Suppl. 2): 31–8.

    Article  CAS  Google Scholar 

  14. Gupta S, Wright HM. Nebivolol: a highly selective β1-adrenergic receptor blocker that causes vasodilation by increasing nitric oxide. Cardiovasc Ther 2008; 26(3): 189–202.

    Article  PubMed  CAS  Google Scholar 

  15. Hillebrand U, Lang D, Telgmann RG, et al. Nebivolol decreases endothelial cell stiffness via the estrogen receptor-β: a nano-imaging study. J Hypertens 2009; 27: 517–26.

    Article  PubMed  CAS  Google Scholar 

  16. Ignarro LJ. Experimental evidences of nitric oxide-dependent vasodilatory activity of nebivolol, a third-generation β-blocker. Blood Press Suppl 2004 Oct; 13 Suppl. 1: 2–16.

    Article  Google Scholar 

  17. Ignarro LJ. Different pharmacological properties of two enantiomers in a unique β-blocker, nebivolol. Cardiovasc Ther 2008; 26: 115–34.

    Article  PubMed  CAS  Google Scholar 

  18. Brett SE, Forte P, Chowienczyk PJ, et al. Comparison of the effects of nebivolol and bisoprolol on systemic vascular resistance in patients with essential hypertension: β-blockade and haemodynamics in hypertension. Clin Drug Investig 2002; 22(6): 355–9.

    Article  CAS  Google Scholar 

  19. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001; 104(5): 511–4.

    Article  PubMed  CAS  Google Scholar 

  20. Mahmud A, Feely J. β-Blockers reduce aortic stiffness in hypertension but nebivolol, not atenolol, reduces wave reflection. Am J Hypertens 2008 Jun; 21(6): 663–7.

    Article  PubMed  CAS  Google Scholar 

  21. Arosio E, De Marchi S, Prior M, et al. Effects of nebivolol and atenolol on small arteries and microcirculatory endothelium-dependent dilation in hypertensive patients undergoing isometric stress. J Hypertens 2002; 20(9): 1793–7.

    Article  PubMed  CAS  Google Scholar 

  22. Evangelista S, Garbin U, Pasini AF, et al. Effect of dl-nebivolol, its enantiomers and metabolites on the intracellular production of superoxide and nitric oxide in human endothelial cells. Pharmacol Res 2007; 55(4): 303–9.

    Article  PubMed  CAS  Google Scholar 

  23. Mason RP, Kalinowski L, Jacob RF, et al. Nebivolol reduces nitroxidative stress and restores nitric oxide bioavailability in endothelium of Black Americans. Circulation 2005 Dec 13; 112(24): 3795–801.

    Article  PubMed  CAS  Google Scholar 

  24. Tran Quang T, Rozec B, Audigane L, et al. Investigation of the different adrenoceptor targets of nebivolol enantiomers in rat thoracic aorta. Br J Pharmacol 2009; 156: 601–8.

    Article  PubMed  CAS  Google Scholar 

  25. Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008 Nov; 21(11): 1251–7.

    Article  PubMed  CAS  Google Scholar 

  26. Pronko TP, Zinchuk VV. Effect of nebivolol on blood oxygen transport indices and endothelial dysfunction in patients with arterial hypertension. Clin Physiol Funct Imaging 2009 May; 29(3): 170–6.

    Article  PubMed  CAS  Google Scholar 

  27. Kamali F, Howes A, Thomas SH, et al. A pharmacokinetic and pharmaco-dynamic interaction study between nebivolol and the H2-receptor antagonists cimetidine and ranitidine. Br J Clin Pharmacol 1997 Feb; 43(2): 201–4.

    Article  PubMed  CAS  Google Scholar 

  28. Gu Z, Robinson RA, Cai L, et al. Metabolism study of 14C-nebivolol in humans with different CYP2D6 genotypes [online]. Available from URL: http://www.aapsj.org/abstracts/AM_2003/AAPS2003-002800.pdf [Accessed 2009 Mar 12].

  29. Lawrence TE, Liu S, Donnelly CM, et al. A phase I open-label multiple dose study assessing the pharmacokinetic interaction of hydrochlorothiazide and nebivolol HCl in healthy volunteers [online]. Available from URL: http://www.aapsj.org/abstracts/Am_2003/AAPS2003-000443.PDF [Accessed 2009 Mar 10].

  30. Lawrence TE, Chien C, Tu HC, et al. No effect of concomitant administration of nebivolol and losartan in healthy volunteers genotyped for CYP2D6 status [abstract no. PII-121]. Clin Pharmacol Ther 2005 Feb; 77(2): 82.

    Article  Google Scholar 

  31. Lawrence TE, Liu S, Bland TM, et al. Single-dose pharmacokinetics and anticoagulant activity of warfarin is unaffected by nebivolol in healthy volunteers [abstract no. PI-121]. Clin Pharmacol Ther 2005 Feb; 77(2): 39.

    Article  Google Scholar 

  32. Lawrence TE, Liu S, Fisher JW, et al. No interaction between nebivolol and digoxin in healthy volunteers [abstract no. PII-98]. Clin Pharmacol Ther 2005 Feb; 77(2): 76.

    Article  Google Scholar 

  33. Morton TL, Liu S, Phillips JL, et al. No pharmacokinetic interaction between nebivolol and furosemide in healthy subjects [abstract no. PII-107]. Clin Pharmacol Ther 2005 Feb; 77(2): 79.

    Article  Google Scholar 

  34. Morton TL, Tu HC, Liu S, et al. Lack of pharmacokinetic interaction between nebivolol and spironolactone [abstract no. PI-148]. Clin Pharmacol Ther 2005 Feb; 77(2): 46.

    Article  Google Scholar 

  35. Morton TL, Liu S, Phillips JL, et al. Pharmacokinetics of nebivolol and ramipril are not affected by co-administration [abstract no. PII-101]. Clin Pharmacol Ther 2005 Feb; 77(2): 77.

    Article  Google Scholar 

  36. Shaw AA, Liu S, Zachwieja LF, et al. Effect of chronic administration of fluoxetine on the pharmacokinetics of nebivolol [abstract no. PI-116]. Clin Pharmacol Ther 2005 Feb; 77(2): 38.

    Google Scholar 

  37. Greathouse MD. Nebivolol efficacy and safety in patients with stage I-II hypertension. Clin Cardiol. In press.

  38. Weiss RJ, Weber MA, Carr AA, et al. A randomized, double-blind, placebo-controlled parallel-group study to assess the efficacy and safety of nebivolol, a novel β-blocker, in patients with mild to moderate hypertension. J Clin Hypertens (Greenwich) 2007 Sep; 9(9): 667–76.

    Article  CAS  Google Scholar 

  39. Saunders E, Smith WB, DeSalvo KB, et al. The efficacy and tolerability of nebivolol in hypertensive African American patients. J Clin Hypertens (Greenwich) 2007 Nov; 9(11): 866–75.

    Article  CAS  Google Scholar 

  40. Neutel JM, Smith DHG, Gradman AH. Adding nebivolol to ongoing anti-hypertensive therapy improves blood pressure and response rates in patients with uncontrolled stage I-II hypertension. J Human Hypertens. Epub 2009 Apr 30.

  41. Papademetriou V. Comparison of nebivolol monotherapy versus nebivolol in combination with other antihypertensive therapies for the treatment of hypertension. Am J Cardiol 2009 Jan 15; 103(2): 273–8.

    Article  PubMed  CAS  Google Scholar 

  42. US FDA. NDA 21742 nebivolol tablets Bertek Pharmaceuticals, Inc. [online]. Available from URL: http://www.fda.gov/cder/foi/nda/2007/021742s000_ MedR_P8.pdf [Accessed 2009 Mar 16].

  43. Gradman AH. Safety and tolerability of nebivolol: a pooled analysis of safety analysis comparing typical β-blocker associated adverse events with placebo. J Clin Hypertens 2008 May 1; 10 (Suppl. A. No. 5): 120.

Download references

Acknowledgments and Disclosures

The manuscript was reviewed by: T. Pronko, Department of Internal Diseases, Grodno State Medical University, Grodno, Belarus; R. J. Weiss, Department of Cardiology, Androscoggin Cardiology Associates, Auburn, Maine, USA; A. Zanchetti, Department of Medicine, University of Milan, Milan, Italy.

The preparation of this review was not supported by any external funding. During the peer review process, the manufacturer of the agent under review was offered an opportunity to comment on this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Author information

Authors and Affiliations

  1. Wolters Kluwer Health ∣ Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore 0754, Auckland, New Zealand

    Claudine M. Baldwin & Susan J. Keam

Authors
  1. Claudine M. Baldwin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Susan J. Keam
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Claudine M. Baldwin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Baldwin, C.M., Keam, S.J. Nebivolol. Am J Cardiovasc Drugs 9, 253–260 (2009). https://doi.org/10.2165/1120274-000000000-00000

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/1120274-000000000-00000

Keywords

Search

Navigation